Rare diseases number in the thousands, yet they seldom grab mainstream attention. Cluster headaches exemplify this oversight, delivering pain so severe it's often called the worst humans endure. Those with the chronic form face unrelenting agony.
Vascular cluster headache (AVF), a little-discussed rare condition, affects nearly 80,000 people in France. It triggers recurrent, intense facial pain—usually around one eye, nose, or temple—in attacks lasting from 15 minutes to several hours.
These headaches strike unilaterally, always on the same side of the face, crossing no midline. Accompanying symptoms often include a red, watery eye, eyelid swelling, nasal congestion, or runny nose. Many patients also experience neck tension, jaw, or tooth pain.
AVF's hallmark is its excruciating intensity, dwarfing other headaches. In a 2001 study, Peter Goadsby, professor of clinical neurology at King's College London, described it as "probably the worst pain that man has ever known." Patient accounts compare it to pain hundreds of times worse than a typical migraine—like an ice pick or screwdriver repeatedly driven through the eye into the brain. A recent French testimony from Diane Wattrelos, published in Ouest-France on February 7, 2021, echoes this horror.
In 80-90% of cases, patients grow restless during attacks, screaming, moaning, or lashing out. Some stay stoic; others harbor suicidal thoughts, occasionally acting on them to escape the torment.
AVF manifests in two forms: episodic or chronic. Episodic attacks cluster for 7-365 days, followed by at least one month of remission. Without such a break for over a year, it turns chronic, affecting about 20% of cases.
Diagnosis proves elusive due to low awareness, with an average delay of 44 months. Notably, 31% of patients wait four years post-onset. The French Society for the Study of Migraines and Headaches (SFEMC) notes causes remain unknown, though triggers like alcohol or irregular sleep are common.
Research implicates the hypothalamus, key to sleep-wake cycles and hormone regulation. During attacks, it abnormally activates facial pain pathways and, reflexively, the autonomic nervous system—explaining tearing eyes, congestion, and related symptoms.
Relief options include injectable sumatriptan, the gold standard, resolving attacks in under 15 minutes for 74% of patients. Yet it fails some.
A petition pushes for Aimovig, a breakthrough therapy approved in the US, Canada, and recently granted European marketing authorization. Costly and unreimbursed by French Social Security, it's unavailable here. With over 67,000 signatures, it heads to Health Minister Olivier Véran upon reaching 75,000.
